Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) | PAR 24 294

Frequently Asked Questions (FAQs)

What is the Blueprint Neurotherapeutics Network (BPN) BPN-Biologics opportunity (PAR-24-294)?

PAR-24-294 is an NIH funding opportunity under the Blueprint Neurotherapeutics Network (BPN) focused on advancing biologic-based therapeutics for disorders of the nervous system. It is designed to help small businesses move a promising biologic therapeutic program from relatively late-stage discovery into key preclinical development activities and, if ready and milestones are met, into Phase I clinical testing.

What is the main goal of this program?

The program functions as a translational bridge to help a small business turn a credible biologic therapeutic concept into a development-ready candidate by supporting lead optimization and IND-enabling development activities, with the option to initiate early clinical evaluation (Phase I) when appropriate.

What funding mechanism is used for this opportunity?

This opportunity uses a cooperative agreement mechanism (U44). Under a cooperative agreement, awardees work in close partnership with NIH program staff and NIH-supported experts as the project progresses through defined development milestones.

How does a cooperative agreement (U44) differ from a standard grant?

Based on the description provided, the U44 structure means the awardee does not simply receive funds and work independently. Instead, the company collaborates closely with NIH program staff and NIH-supported experts, and the project advances through milestone-driven development with active involvement and support from NIH-associated resources.

Is this program focused on small molecules or biologics?

The scope is specifically focused on biologic or biotechnology-derived therapeutics rather than traditional small molecules. The opportunity explicitly supports multiple biologic modalities intended to treat disorders of the nervous system.

What types of therapeutics are explicitly included?

The FOA explicitly includes large biologic macromolecules such as proteins, antibodies, and peptides. It also includes gene-based approaches such as oligonucleotide therapies and viral vector-based therapies. In addition, it supports cell therapies and newer or emerging modalities, including microbial or microbiome-based therapeutics, as long as the goal is an intervention for disorders of the nervous system.

Are gene-based therapies included under this opportunity?

Yes. The described scope includes gene-based approaches such as oligonucleotide therapies and viral vector-based therapies, provided the program is aimed at developing a therapeutic intervention for nervous system disorders.

Are cell therapies eligible under this program?

Yes. Cell therapies are specifically mentioned as supported modalities within the biologic-focused scope of the program.

Are microbiome-based therapeutics eligible under this program?

Yes. Microbial or microbiome-based therapeutics are identified as supported emerging modalities, provided they are intended to develop an intervention for disorders of the nervous system.

What stage of development is this funding intended to support?

The program is intended to support projects moving from relatively late discovery work through lead optimization and key preclinical development activities. It is oriented toward building an IND-enabling package and may support progression into Phase I clinical testing if the project is ready and achieves required benchmarks.

Does the program support Phase I clinical testing?

It can. The opportunity is designed with an option to progress through Phase I clinical testing when the project is ready and when required benchmarks and development milestones are achieved.

What is meant by “milestone-driven” development in this program?

The program is described as moving projects through defined development milestones and required benchmarks. In practical terms, this indicates progress is expected to be measured against specific development goals as the candidate advances through optimization, preclinical development, and potentially into Phase I clinical testing.

What kinds of development activities can be supported?

The description highlights development work central to biologics advancement toward regulatory readiness, including lead optimization and preclinical development activities needed for an IND-enabling package. It also notes specialized areas that can be supported through program infrastructure, such as manufacturing and scale-up, pharmacokinetics, toxicology, and Phase I clinical testing.

What development infrastructure is available through BPN-Biologics?

A key feature is built-in development infrastructure. Awardees are expected to collaborate with NIH-funded consultants, and projects can be augmented through NIH contract research organizations (CROs) with specialized capabilities that may be expensive or difficult for small businesses to assemble on their own.

What kinds of CRO capabilities can be accessed through the program?

The described CRO resources can cover areas central to biologics development, including manufacturing and scale-up, pharmacokinetics, toxicology, and Phase I clinical testing.

Why does the program emphasize access to NIH-supported consultants and CROs?

The stated intent is to reduce common bottlenecks that slow biologics programs and to improve the quality and regulatory readiness of the data package by leveraging experienced development partners and specialized capabilities.

Who can apply for PAR-24-294?

Eligibility is limited to small businesses, consistent with the SBIR/STTR-style U44 mechanism described in the opportunity summary.

Are foreign organizations eligible to apply?

No. Foreign organizations (non-U.S. entities) are not eligible to apply under this opportunity as described.

Can a U.S. small business include non-domestic components?

No. The summary states that non-domestic components of U.S. organizations are also not eligible.

Are any international elements allowed at all?

The summary notes that “foreign components” may be allowed under NIH policy. This generally means certain project elements could potentially be carried out abroad if they meet NIH requirements and receive appropriate approval, but the applicant organization itself must be U.S.-based and eligible as a small business.

How does intellectual property (IP) work under this program?

The program highlights an IP structure described as a benefit: awardee institutions retain their existing IP rights, and they also receive assignment of IP rights from the BPN-Biologics contractors for biotherapeutic candidates developed under the program. This structure is positioned to support awardee control over patent prosecution and licensing negotiations.

Why is the IP structure important for small businesses?

The summary explains that maintaining strong control over resulting IP can be critical for small businesses that need to raise investment, secure partnerships, or plan commercialization pathways.

Is this funding opportunity a new announcement?

The announcement is described as a reissue of PAR-21-233, indicating it is an updated or reissued version of a prior funding opportunity.

Which agency is sponsoring this opportunity?

The sponsor is the National Institutes of Health (NIH), and the opportunity is described as NIH-wide in nature through the Blueprint effort, with involvement of multiple institutes and centers that support neuroscience and neurological disorder research.

Are there CFDA numbers associated with this opportunity?

Yes. The opportunity is described as listing multiple CFDA numbers, reflecting the NIH-wide nature of the Blueprint effort and the involvement of multiple institutes and centers.

What is the application deadline for PAR-24-294?

The FOA has an original closing date of August 18, 2027, providing a multi-year window to apply under the program’s submission schedule.

Is there a stated award ceiling or expected number of awards?

In the excerpt provided, there is no stated award ceiling or expected number of awards. The summary notes that the cooperative agreement structure and CRO access indicate support for substantial translational work and milestone-driven development.

What types of projects are a good fit for this opportunity?

Projects are a good fit when they involve biologic or biotechnology-derived therapeutic candidates intended for disorders of the nervous system and are ready to advance from relatively late discovery into lead optimization and IND-enabling development, with the potential to move into Phase I testing if readiness and milestones support it.

Is this program intended for early exploratory research?

The description emphasizes substantial translational work, milestone-driven development, and building a regulatory-ready IND-enabling package, rather than early exploratory research.

What is the overall value proposition of PAR-24-294 for a small business?

Based on the provided description, the overall value proposition is a combination of funding and hands-on development support (including NIH collaboration, NIH-funded consultants, and NIH CRO resources) to push a biologic therapeutic candidate through preclinical development and, when appropriate, into Phase I clinical testing, while allowing the awardee to maintain strong control over resulting IP.